Lombard Medical Announces Successful Completion of First 15 Cases in Japan for IntelliFlex LP Delivery System for the Aorfix™ Endovascular Stent Graft

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

Lombard Medical, Inc. a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that physicians in Japan have successfully treated the first 15 patients using its innovative new IntelliFlex™ LP Delivery System for the Aorfix™ Endovascular Stent Graft since launch on February 1, 2017.

Lombard Medical reports the Aorfix with IntelliFlex is exclusively distributed in Japan by Medico’s Hirata Inc., one of the country’s leading suppliers of vascular products with proven expertise in building significant market share for AAA stent grafts.

IntelliFlex is used in conjunction with the Aorfix endovascular stent graft, the only AAA stent graft with global regulatory approvals to treat aortic neck angulation up to 90 degrees. IntelliFlex is designed to be easy and intuitive to use, is low profile and compact, and incorporates numerous ergonomic features designed in collaboration with physicians.

Dr. Naoki Toya, Consultant Vascular Surgeon, Tokyo Jikei University Kashiwa Hospital, commented, “We have had good experience with the Aorfix stent graft and now following our initial cases with the new IntelliFlex delivery system, we are extremely impressed by the control and precision of placement with the new technology.”

“Gaining Japan regulatory approval for the IntelliFlex LP Delivery System has been a primary strategic goal for the company. With that in hand, we are excited by the potential for growth in our business in Japan for the Aorfix stent graft now paired with IntelliFlex and its significant advantages,” said Lombard Medical CEO Simon Hubbert. “We continue to innovate and expand the capabilities of our core technologies in key global markets and look forward to seeing the benefits of IntelliFlex reflected from our customers’ experience and patient outcomes.”

Japan is the world’s second largest standalone EVAR market, is estimated at 10% of the global market and has been growing at an average rate of approximately 18%. In Japan, there are approximately 400 physicians at 200 clinics performing EVAR and it is estimated that approximately 55% of Japanese AAA patients are treated using this method.1

About Aorfix Endovascular Stent Graft
Aorfix is an endovascular stent graft system for treating infra-renal aortic and aorto-iliac aneurysms, also known as abdominal aortic aneurysms (AAAs). When placed within the aneurysm, Aorfix creates an internal bypass of the aneurysm to reduce the risk of rupture. Aorfix is the first and only endovascular stent graft with global approvals for the treatment of patients with aortic neck angulations up to 90 degrees. Aorfix features an exclusive helical and circular design that allows it to conform to the natural contours of human anatomy, including aortic necks with high angulations and iliac arteries with extreme bends. Aorfix has been evaluated in three studies and used in more than 7,000 procedures worldwide. Aorfix has a CE Mark, Japan regulatory approval, and received FDA approval in 2013.

About Abdominal Aortic Aneurysms (AAAs)
AAAs are balloon-like enlargements of the aorta which if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAAs in the developed world and each year more than 500,000 new cases are diagnosed. In the U.S., aortic aneurysm disease is among the leading causes of death and it is estimated that 1.5 million people have an abdominal aortic aneurysm.

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.